Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer  by Wang, Jun et al.
ters. In addition, diffusing capacity, exercise capacity,
and oxygen consumption during exercise have recently
been shown to be important independent predictors of
operative mortality and pulmonary morbidity.1-6
The focus of patient assessment has recently expand-
ed to include long-term outcomes. Although tumor
stage has always been taken into account in such an
assessment, physiologic parameters have not been used
extensively in this regard. It has recently been shown
that diffusing capacity predicts intermediate-term mor-
bidity in patients undergoing major resection for lung
cancer.7 In addition, diffusing capacity has been shown
to be a predictor of long-term survival in patients with
severe emphysema.8-10 Patients with lung cancer have a
diminished diffusing capacity compared with the gener-
al population, but whether diffusing capacity influences
long-term outcome after major lung resection is un-
T he appropriate selection of patients with lung cancerfor major lung resection is a continuing challenge.
The primary focus has been on reducing surgical mor-
tality and complications, which for many years has
been accomplished by the use of a general assessment
of the patient and measurement of spirometric parame-
Objectives: We sought to determine whether diffusing capacity influences
operative mortality and long-term survival after resection for lung can-
cer. Methods: We retrospectively reviewed the case histories of patients
who underwent major resection for lung cancer. The association
between operative mortality and predicted postoperative diffusing
capacity was examined. Long-term survival among operative survivors
was compared between the groups with high and low predicted postop-
erative diffusing capacity. Results: The group comprised 410 patients
with a mean age of 62.3 years. We performed 273 lobectomies, 35
bilobectomies, and 102 pneumonectomies. A total of 32 operative deaths
(7.8%) were associated with low predicted postoperative diffusing
capacity (P < .001). If we examine only operative survivors, there is no
significant difference in survival data between patients with a predicted
postoperative diffusing capacity of less than 50 and those with a pre-
dicted figure of 50 or more (stage I, 111 vs 90 months; stage II, 26 vs 32
months; stage IIIa 32 vs 26 months; log rank P > .5 for each). On the
basis of the Cox proportional hazards model, predicted postoperative
diffusing capacity did not have a statistically significant effect on long-
term survival (estimated hazard ratio corresponding to a 20-point
decrease in predicted postoperative diffusing capacity = 1.13; 95% con-
fidence interval: 0.92 to 1.37). Conclusion: A poor diffusing capacity is
associated with high operative mortality but does not adversely affect
long-term survival after major lung resection among operative sur-
vivors. Improving the perioperative management of patients undergoing
major lung resection may enable inclusion of more patients with
reduced diffusing capacity in the candidate pool for surgery, thus max-
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DIFFUSING CAPACITY PREDICTS OPERATIVE MORTALITY BUT NOT LONG-TERM SURVIVAL AFTER
RESECTION FOR LUNG CANCER
known.11 We performed a retrospective analysis of
long-term survival in patients who have undergone
major resection for lung cancer to address this issue.
Patients and methods
We performed a retrospective analysis of patients who
underwent major lung resection (lobectomy, bilobectomy, or
pneumonectomy) at the University of Chicago from January
1980 through June 1997. Data were recorded for preoperative
and operative risk factors as previously described.5 Spirom-
etry and measurement of total lung capacity and single-breath
diffusing capacity for carbon monoxide were performed as pre-
viously described.2 Predicted postoperative diffusing capacity
(ppoDLCO%) was calculated by multiplying the percent of
predicted normal for each patient by the fraction of functional
lung segments remaining after resection. Functional lung seg-
ments were assigned as described previously.5
Patients were staged according to the American Joint
Commission on Cancer12 staging system. Data on postopera-
tive morbidity and mortality were recorded and operative
mortality was defined as death during hospitalization for the
operation or within 30 days of the operation. The relationship
between ppoDLCO% and operative mortality was examined
by fitting a stepwise regression model. Candidate covariates
in addition to ppoDLCO% were age, sex, performance status,
type of operation, stage, and pathology (squamous cell can-
cer, adenocarcinoma, or other).
Survival was calculated from the day of operation by
means of the Kaplan-Meier method.13 For the analysis of all
patients and of operative survivors only, based on previously
published calculations regarding risk of mortality and its rela-
tionship to ppoDLCO%, patients were divided into two
groups with ppoDLCO% = 50 as a cutoff point. The groups
were compared by means of the log rank test with stratifica-
tion according to stage.5,14 The relationship between
ppoDLCO% and long-term survival was also examined with
the Cox proportional hazards model, treating ppoDLCO% as
a continuous variable and adjusting for age, sex, performance
status, operation type, stage, and pathology, by means of a
backward elimination procedure.15 Inspection of Martingale
residuals indicated that the untransformed values of
ppoDLCO% and age provided an adequately fitting model.16
The proportional hazards assumption was checked by includ-
ing interaction terms between each covariate and (log) sur-
vival time, as well as through examination of Schoenfeld
residuals.17 None of the interaction terms was statistically
significant, and the residual plots indicated that the propor-
tional hazards assumption was reasonable. All statistical cal-
culations were performed with Minitab 10.5 (Minitab, Inc,
State College, Pa), Systat 7.0 (SPSS, Inc, Chicago, Ill), or
SAS (SAS Institute, Inc, Cary, NC) software. Data are
expressed as mean ± standard deviation.
Results
The group comprised 410 patients (242 men, 168
women) with a mean age of 62.3 ± 9.9 years (range 35-
87 years). Included were 196 patients with squamous
cell cancer, 186 with adenocarcinoma, and 14 each
with large cell cancer or bronchoalveolar carcinoma.
The mean preoperative diffusing capacity expressed as
a percent of predicted (available in 334 patients; data
were missing for the remaining patients) was 85.9 ±
21.9 (range 21-171) and the mean ppoDLCO% was
61.4 ± 18.8 (range 11.1-132.3; 334 patients).
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Fig 1. Estimated operative mortality after major pulmonary
resection for non–small cell lung cancer as a function of the
predicted postoperative diffusing capacity expressed as a per-
cent of predicted (ppoDLCO%) for 334 patients. Solid line,
Estimated from logistic regression model; dashed lines, 95%
confidence limits.
Fig 2. Kaplan-Meier survival curves by stage after major pul-
monary resection for non–small cell lung cancer. Vertical
hash marks represent censored values. Error bars depict 95%
confidence limits (P < .001). The number of deaths was 71,
46, and 89 in stage I, stage II, and stage IIIa, respectively.
Patients in whom diffusing capacity was not mea-
sured were more likely to have been operated on dur-
ing the first 6 years of the study period compared with
either of the latter 6-year intervals (P < .001 by c 2
analysis). In addition, they had lower forced vital
capacity (2.89 ± 0.11 vs 3.28 ± 0.05 L; P = .002), a
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Fig 3. A to C, Kaplan-Meier survival curves by stage after
major pulmonary resection for non–small cell lung cancer.
Patients with a predicted postoperative diffusing capacity
expressed as a percent of predicted (ppoDLCO%) of < 50 are
compared with patients with a ppoDLCO% ‡ 50. Vertical








Fig 4. A to C, Kaplan-Meier survival curves by stage for
operative survivors after major pulmonary resection for
non–small cell lung cancer. Patients with a predicted postop-
erative diffusing capacity expressed as a percent of predicted
(ppoDLCO%) of < 50 are compared with patients with a
ppoDLCO% ‡ 50. Vertical hash marks represent censored
values. Error bars represent 95% confidence limits.
lower forced vital capacity expressed as a percent of
predicted (77.7% ± 3.2% vs 87.1% ± 0.9%; P = .006),
and a lower forced expiratory volume in 1 second
(FEV1; 2.06 ± 0.08 vs 2.25 ± 0.04 L; P = .036) than did
the patients who had diffusing capacity measured. The
two groups of patients were not significantly different
in terms of age, sex, FEV1 expressed as a percent of
predicted, type of operation, cancer cell type, or patho-
logic stage.
Lobectomy was performed in 273 patients, bilobec-
tomy in 35, and pneumonectomy in 102 patients. The
pathologic stage was I in 184 patients, II in 68, IIIa in
143, IIIb in 8, IV in 4 patients, and was unknown in 3
patients. The mean postoperative length of stay was
11.6 ± 10.0 days (range 0-120 days), which decreased
linearly from 14.5 ± 8.1 days during the years 1980 to
1984 to 8.3 ± 10.4 days for operations performed since
January 1995. The mortality rate was 7.8% (32
patients), which also decreased linearly from 8.8%
(13/148) during the years 1980 to 1984 to 5.6% (4/71)
for operations performed since January 1995. The oper-
ative mortality rate was similar for patients who had
diffusing capacity measured and for those who did not
(7.4% vs 9.2%; P = .61). The mortality rate was close-
ly related to the ppoDLCO% (Fig 1). The unadjusted
odds ratio corresponding to a 20-point decrease in
ppoDLCO% was 2.7 (95% CI: 1.6-4.6). From the mul-
tivariable logistic regression analysis, the odds of death
are estimated to increase 3.5-fold (95% CI: 1.9-6.2) for
every 20-point decrease in ppoDLCO% after adjust-
ment for patient age (age was the only significant pre-
dictor [P = .014] among the remaining covariates).
The mean follow-up was 37.2 months (range 0-214
months). Survival by stage for all patients is shown in
Fig 2. Survival by stage for all patients with diffusing
capacity measured and separating patients into higher-
risk and lower-risk ppoDLCO% groups demonstrated
no statistically significant difference in survival be-
tween the two groups within each stage (stages I, II,
and IIIa only; 322 patients; Fig 3; log rank P > .25 for
each). Median survival times for patients with
ppoDLCO% < 50 and ppoDLCO% ‡ 50 were as fol-
lows: stage I, 83.8 versus 88.1 months; stage II, 13.0
versus 27.8 months; stage IIIa, 21.7 versus 25.4 months.
Median survival times for patients surviving surgery
with diffusing capacity measured and separating
patients into higher-risk and lower-risk ppoDLCO%
groups (ppoDLCO% < 50 and ppoDLCO% ‡ 50) were
as follows: stage I, 111.3 versus 89.6 months; stage II,
26.5 versus 31.9 months; stage IIIa, 31.6 versus 25.8
months. No difference in survival was detected between
the two groups within each stage (Fig 4; log rank > 0.5
for each).
Using ppoDLCO% as a continuous variable in a mul-
tivariable Cox proportional hazards model, we also
found no statistically significant effect of ppoDLCO%
on long-term survival. The relative death rate for a 20-
point decrease in ppoDLCO% was 1.13 (95% CI 0.92-
1.37) and for a 30-point decrease in ppoDLCO%, 1.19
(95% CI 0.89-1.61). The only significant predictors of
increased mortality were more advanced pathologic
stage (P < .001) and increased age at operation (relative
death rate per 10-year increase in age = 1.31; 95% CI
1.09-1.58, P = .003).
Discussion
The traditional assessment of patients with lung can-
cer who are candidates for major lung resection has
focused primarily on estimating the risk of operative
mortality and perioperative morbidity. This has been
accomplished by means of a general evaluation of age
and performance status, measurement of spirometric
values, and, recently, evaluation of gas exchange para-
meters such as diffusing capacity or a measurement of
exercise capacity or oxygen consumption during exer-
cise.1-6 The long-term outcome after operation has been
584 Wang, Olak, Ferguson The Journal of Thoracic and
Cardiovascular Surgery
March 1999
Table I. Postoperative predicted DLCO values for patients by risk group and stage
Stage I Stage II Stage IIIa Stages IIIb, IV All stages
ppoDLCO% <50
Patients 30 15 43 5 93
ppoDLCO% 41.9 ± 5.4 39.6 ± 7.6 37.2 ± 8.7 42.2 ± 8.1 39.3 ± 7.7
ppoDLCO% >50
Patients 127 40 67 5 239
ppoDLCO% 71.9 ± 15.3 69.3 ± 13.4 67.2 ± 12.5 68.3 ± 8.3 70.0 ± 14.2
All patients
Patients 157 55 110 10 332*
ppoDLCO% 66.1 ± 18.3 61.2 ± 18.0 55.5 ± 18.5 55.3 ± 15.8 61.4 ± 18.8
ppoDLCO%, Calculated postoperative diffusing capacity expressed as a percent of predicted.
*Cell type for two patients was not known.
estimated primarily on the basis of patient age, general
performance status, and pathologic stage. Using a com-
bination of all of these factors, surgeons make important
judgments regarding operability in individual patients.
During the past several years a trend has developed
that emphasizes the inclusion of intermediate- and
long-term outcome expectations in the initial assess-
ment of the candidate for major lung resection. Age has
been shown to be a factor that determines operative
mortality and early postoperative morbidity, as was
found in our study.5,18,19 Evaluating operative survivors
only, the long-term survival by stage for older com-
pared with younger patients has been shown to be sim-
ilar.20-23 However, we detected a highly significant
effect of age on long-term survival. Similarly, a low
diffusing capacity predicts a higher incidence of post-
operative pulmonary complications and, in some
reports, operative mortality.1,2,5,7 A low diffusing
capacity predicts a higher likelihood of pulmonary
complications in the intermediate term, which require
either supplemental oxygen or hospitalization, and a
worse dyspnea score. Patients with a lower diffusing
capacity also may have a worse long-term survival than
those with a normal diffusing capacity.7
The focus on diffusing capacity is appropriate.
Patients with lung cancer have lower diffusing capaci-
ties than patients without lung cancer who have similar
spirometric values and a similar smoking history, sug-
gesting that patients with lung cancer have more severe
but still subclinical emphysema.11 Diffusing capacity is
inversely related to the mortality rate in patients with
severe emphysema.1,2,5 On the basis of these findings,
we thought it appropriate to investigate the relationship
of diffusing capacity to long-term survival in patients
undergoing major lung resection for lung cancer.
We found that in our series of patients the ppo-
DLCO% was strongly associated with the risk of oper-
ative mortality, confirming previous reports by us and
others.1,2,5 However, in patients who survived major
lung resection, the ppoDLCO% did not have a statisti-
cally significant influence on long-term survival after
adjusting for stage of disease and age at the time of
operation. The reasons for this discrepancy are not
immediately clear. Patients who undergo major lung
resection for cancer have higher diffusing capacities,
on average, than patients with end-stage emphysema,
in whom a low diffusing capacity is associated with a
decreased long-term survival. This may explain why
patients with lung cancer avoid the detrimental influ-
ence of diffusing capacity on long-term survival. It is
also possible that the increased operative mortality
associated with a low diffusing capacity in the patients
undergoing lung resection skews the survival curves by
eliminating patients who would have a poorer long-
term survival on the basis of their diffusing capacity.
Were these patients to survive an operation, a detri-
mental effect of low diffusing capacity on subsequent
survival might become apparent. However, recent
reports suggest that long-term survival in some patients
with severe underlying lung disease may actually be
improved with lung resection, mirroring some of the
effects seen with lung volume reduction surgery in
patients with severe emphysema.24-29 In any case, on
the basis of the upper confidence limits, an increase in
the death rate of as much as 37% for a 20-point reduc-
tion in diffusing capacity and an increase in the death
rate of as much as 61% for a 30-point reduction in dif-
fusing capacity are consistent with our data. Thus larg-
er studies are needed to confirm our results.
The finding of a low ppoDLCO% in a patient has
been interpreted by some physicians to mean that the
patient is not a candidate for major lung resection.
However, the use of ppoDLCO% has not been prof-
fered as an absolute measure of a patient’s ability to
withstand surgery, but merely as one means, albeit an
important one, to assess relative risk of operative mor-
bidity and mortality. In fact, a number of improvements
in intraoperative and postoperative management of
patients with compromised pulmonary status have been
developed in recent years in conjunction with the
increasing clinical experience in lung transplantation
and lung volume reduction surgery for emphysema.
These advances will likely reduce the risk of operative
morbidity and mortality of major lung resection over
time, possibly reducing the negative influence that
ppoDLCO% has on these outcomes.
Resection remains the optimal therapy for early-stage
lung cancers. It is important that surgical therapy be
offered to as many patients with early-stage lung can-
cer as possible, commensurate with their risk of peri-
operative complications and the expected benefit to
them in long-term survival. It is incumbent on surgeons
and other physicians to further improve the current
techniques of perioperative management so that
patients who are at higher operative risk on the basis of
a marginal ppoDLCO% can be safely included in the
candidate pool for surgery. Assuming that operating on
more patients with reduced diffusing capacity would
not adversely affect long-term survival figures, survival
in the patient with early-stage lung cancer should
improve.
We gratefully acknowledge the assistance of Theodore
Karrison, PhD, for assisting in the statistical analyses.
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Discussion
Dr Joseph I. Miller, Jr (Atlanta, Ga). I congratulate Dr
Jun Wang and his coauthors on an excellent manuscript. Dr
Wang is the 1997-1998 Evarts A. Graham Fellow, and this
presentation is one of his many accomplishments during his
year in the United States.
This paper marks the completion of a trilogy for Dr
Ferguson and his colleagues from the University of Chicago.
In 1988 Dr Ferguson presented a paper before the Association
entitled “Diffusing Capacity Predicts Mortality and
Morbidity After Pulmonary Resection.” In 1994 he presented
before the Association a paper entitled “Optimizing Selection
of Patients for Major Lung Resection,” at which time he first
introduced the concept of ppoDLCO%. He also pointed out
at that time that this was the most specific indicator of post-
operative morbidity and mortality, but there was also no cor-
relation between it and use of percent predicted FEV1 as a
postoperative indicator. This current paper marks the comple-
tion of an outstanding series of investigative and statistical
studies on diffusing capacity and ppoDLCO%. 
I have several questions. In this excellent statistical study,
the ppoDLCO% correlates well with early morbidity and
mortality but is not an indicator of long-term survival. In
making this assumption, you have taken out the cohort of
patients dying early, that is, 32 patients, or 7.2% of the total
series that were stated to be operative deaths. Do you think
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there would have been any difference in the statistics had this
operative cohort of 32 patients been included with your
analysis? 
From studies on chronic obstructive pulmonary disease, we
know that an FEV1 of less than 30% of predicted or a diffus-
ing capacity of less than 30% of predicted correlates well
with a 5-year survival of less than 50%. In the era of lung vol-
ume surgery, we know that the lower the diffusing capacity,
the greater the risk of morbidity and mortality. The current
study correctly points out that a low diffusing capacity should
not be the only criterion for operability; rather, a number of
parameters should be evaluated. 
My questions, then, are these: Do you think that if the oper-
ative cohort of 37 patients had been left in the total group the
statistics would have been different? Do you use oxygen con-
sumption as an indicator of operability in your marginal
cases? What parameter other than ppoDLCO% do you think
is helpful in deciding resectability in marginal cases? In
patients in the marginal group whom you are considering for
pulmonary resection, patients who have both low diffusing
capacities and low flow rates, do you think a right heart
catheterization would ever be indicated to rule out pulmonary
hypertension?
Your mean diffusing capacity was 85.9%, or 86% ± 21%,
and the mean ppoDLCO% was 61. This is a much higher dif-
fusing capacity than we usually see in our patients with lung
cancer. In general, our mean preoperative diffusing capacity
would be in the range of 60% to 70% of predicted. There
seems to be a discrepancy in the patient population between
Chicago and Atlanta. 
In your manuscript, you state that patients are divided into
four risk groups according to their ppoDLCO%. I did not see
that list given today. Can you tell us what these divisions are
and what the risks are within each group? 
Dr Wang. Dr Miller, thank you for your kind comment and
your many good questions. 
You questioned the use of oxygen consumption as a pre-
dictor of risk. Our previous study, presented at the meeting of
the American College of Chest Physicians in 1997, showed
that the diffusing capacity predicted postoperative morbidity
better than oxygen consumption did. Other parameters that
we used to assess risk included FEV1, age, and general per-
formance status. 
Regarding right heart catheterization, we do not often see
these kinds of problems. If pulmonary hypertension is sus-
pected, the initial evaluation is echocardiography. If the pres-
sure is abnormal, right heart catheterization is the preferred
procedure. 
As for your question about the mean diffusing capacity, in
our study, 25% of patients had a ppoDLCO% of less than 50.
There may be a difference between the institutions in patient
population. 
The four risk groups identified in assessing the risk of opera-
tive mortality relative to the ppoDLCO% were those with a
ppoDLCO% less than 40, 40 to 50, 50 to 60, and greater than 60. 
We included the operative deaths to determine in an isolat-
ed way how ppoDLCO% might influence long-term survival,
assuming the patients survived the operation. Because
ppoDLCO% predicts operative mortality, there was a differ-
ence between the groups in long-term survival when opera-
tive deaths were included in the analysis.
Age is an important determinant of operative mortality but
does not appear to have much influence on long-term survival
in operative survivors. Similarly, the ppoDLCO% influences
operative mortality but not long-term survival. It is our job to
improve preoperative management to reduce the predictable
operative mortality.
Dr Larry R. Kaiser (Philadelphia, Pa). I noted that 25%
of the resections were pneumonectomies and another 8% or
9% were bilobectomies. Thus almost 35% of the patients had
procedures that are associated with a higher mortality.
Is your ppoDLCO% based on the operation you think the
patient is going to have, is the prediction done prospectively,
or is this postoperatively predicted after the resection is done?
Did the number of pneumonectomies, which is a little high,
explain the survival difference?
Dr Ferguson. The percentage of extended resections is
somewhat higher than most investigators have reported, but it
did not appear to influence long-term outcome in our
patients. Most of these numbers were not measured. They
were calculated on the basis of the type of resection that was
performed.
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